in prostate cancer Donata Villari Azienda Ospedaliera Universitaria Careggi Firenze
|
|
- Avis Mitchell
- 8 years ago
- Views:
Transcription
1 surgery as primary treatment in prostate cancer Donata Villari Sod Urologia II Azienda Ospedaliera Universitaria Careggi Firenze
2 Prostatectomia radicale (PR) Terapia "gold standard del tumore prostatico localizzato mediante rimozione in blocco di prostata e vescicole seminali Life expectancy >10 anni Età 75 anni (?) Stadio ct1b-t2, T2 N0, M0 T3a, GS>8, PSA<20ng/mL Prostatectomia retropubica open Prostatectomia videolaparoscopica Prostatectomia robotica
3 Stadiazione clinica accurata - il paziente ideale Età e performance status Familiarità ER PSA alla diagnosi Gleason score bioptico, numero e sede dei frustoli positivi T clinico IIEF-5
4 Fig. 4 Number of men aged 70 years and 80 years in more developed countries. Men over the age of 70 years are the fasted growing segment of the population. Data from 2010 to 2050 are projections <ce:cross-ref refid="bib8"> [8]</ce:cross-ref>. Jean-Pierre Droz, Lodovico Balducci, Michel Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michae... Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults Critical Reviews in Oncology/Hematology, Volume 73, Issue 1, 2010, 68-91
5 Fig. 6 Life expectancy in senior adults: a large variability reflecting health status variability. For a given age, a proportion of men in the top 25th percentile have a good health status and may have a longer life expectancy than men who are 5, 10 or eve... Jean-Pierre Droz, Lodovico Balducci, Michel Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michae... Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults Critical Reviews in Oncology/Hematology, Volume 73, Issue 1, 2010, 68-91
6 Fig. 7 General scheme for the treatment decision-making in senior adults with prostate cancer. Jean-Pierre Droz, Lodovico Balducci, Michel Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michae... Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults Critical Reviews in Oncology/Hematology, Volume 73, Issue 1, 2010, 68-91
7 Fig. 7 General scheme for the treatment decision-making in senior adults with prostate cancer. Jean-Pierre Droz, Lodovico Balducci, Michel Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michae... Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults Critical Reviews in Oncology/Hematology, Volume 73, Issue 1, 2010, 68-91
8
9 2014
10
11 Low risk < 25% PSA failure ng/ml T2a and Gleason 6 and PSA < 10 Intermediate risk 25-50% PSA failure T2b or Gleason 7 or PSA ng/ml High risk > 50 % PSA failure T2c or Gleason 8-10 or PSA> 20 ng/ml
12 Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment J Urol Matthew R. Cooperberg,* Jeannette M. Broering,* Philip W. Kantoff and Peter R. Carroll, 7 Biochemical survival among radical prostatectomy patients with low risk prostate cancer. Kaplan Meiercurvesfor biochemical recurrence free survivalamongamong patients with low risk prostate cancer undergoing radical prostatectomy, stratified by Cancer of the Prostate Risk Assessment (CAPRA) score.
13 L importanza delle categorie di rischio J Clin Oncol 2011 Click to edit the outline text format Second Outline Level Third Outline Level Fourth Outline Level Fifth Outline Level
14 La stadiazione clinica VOLUME GLEASON + PSA = STADIO PRESUNTO Partin AW Combination of Prostate-specific antigen,clinical stage, and Gleason score to predict pathological stage of localized prostate cancer :a multiisituzional update JAMA 1997
15
16 VOLUME DELLA NEOPLASIA
17 PENETRAZIONE CAPSULARE T2 (intra) T3(extra) T3(extra) T2 (intra)
18 Very promising technique Useful in selected cases. Could suggest to perform first or repeated biopsy
19
20 2014
21 Fascio vasculo-nervoso T1 T2
22
23 Achieving the balance between preserving the neurovascular bundles and eliminating the entire tumour continues to be a difficult task. The more the crucial structures are spared, the higher the chance that parts of the tumour will be left behind.
24 Trifecta outcomes in radical prostatectomy series according to the literature
25 Quality of life Fig. 1 Patient flow chart. CaPSURE = Cancer of the Prostate Strategic Urologic Research Endeavor; QoL = quality of life. Sanoj Punnen, Janet E. Cowan, June M. Chan, Peter R. Carroll, Matthew R. Cooperberg Long-term Health-related Quality of Life After Primary Treatment for Localized Prostate Cancer: Results from the CaPSURE Registry European Urology, 2014 Median follow up:74 mo (50 102)
26 Adjusted mean summary scores for the Medical Outcomes Studies 36-item Short Form (a) physical function and (b) mental health, and for the University of California, Los Angeles, Prostate Cancer Index (c) sexual function, (d) sexual bother, (e) urinary function, (f) urinary bother, (g) bowel function, and (h) bowel bother are displayed over time by primary treatment type among 3294 men in the study cohort. BT =brachytherapy; EBRT =external beam radiotherapy; NSRP = nervesparing radicalprostatectomy;nonnsrp=non t t N NSRP nerve sparing radical prostatectomy PADT = primary androgen deprivation therapy; PRE = before treatment; WW/AS = watchful waiting/active surveillance. Sanoj Punnen, Janet E. Cowan, June M. Chan, Peter R. Carroll, Matthew R. Cooperberg Eur Urol 2014 Long-term Health-related Quality of Life After Primary Treatment for Localized Prostate Cancer: Results from the CaPSURE Registry
27 Mean health-related quality of life summary scores at baseline for 3294 men in the study cohort by primary treatment modality BT = brachytherapy; EBRT = external beam radiotherapy; NSRP = nerve-sparing e radical prostatectomy; PADT = primary androgen deprivation therapy WW/AS = watchful waiting/active surveillance Health NSRP Non NSRP NSRP BT EBRT PADT WW/AS domain SF 36 Physical 93 (14) 88 (19) 82 (22) 78 (23) 74 (24) 71 (29) function Mental health UCLA PCI Sexual function 79 (16) 78 (16) 79 (15) 81 (15) 80 (16) 77 (19) 65 (26) 54 (28) 43 (30) 35 (28) 32 (26) 32 (28) Sexual bother 71 (34) 61 (37) 54 (39) 53 (40) 55 (41) 44 (41) Urinary 93 (12) 93 (13) 92 (13) 91 (14) 90 (16) 87 (22) function Urinary bother 89 (19) 85 (24) 83 (24) 81 (27) 79 (28) 77 (33) Bowel 90 (12) 88 (14) 88 (14) 87 (13) 84 (17) 86 (17) function Bowel 93 (16) 90 (20) 88 (21) 86 (23) 83 (25) 87 (22) bother Data are shown as mean (standard deviation).
28
29
30
31
32
33 2014
34
35 CHIRURGIA ROBOT-ASSISTED IN ITALIA L Italia è il secondo paese in Europa e il quarto nel mondo per numero di robot «Da Vinci» attualmente in uso: 1.U.S.A. (2000) 2.Giappone (138) 3.Francia (69) 4.Italia (64) Oltre 9000 procedure robotiche eseguite in Italia nel 2013
36 POLO DI CHIRURGIA ROBOTICA DELLA REGIONE TOSCANA procedure a Settembre2014 Dept. Of Urology, AOUC Careggi, Florence
37 POLO DI CHIRURGIA ROBOTICA DELLA REGIONE TOSCANA Stratificazione per tipo di intervento Dept. Of Urology, AOUC Careggi, Florence
38 POLO DI CHIRURGIA ROBOTICA DELLA REGIONE TOSCANA Vantaggi dell impiego del sistema robotico monodisciplinare in struttura con alto volume operatorio Rapida acquisizione di casistica adeguata Riduzionedella della curva diapprendimento Formazione rapida di una equipe Miglioramento outcomes oncologici e funzionali e riduzione dei costi
39 POLO DI CHIRURGIA ROBOTICA DELLA REGIONE TOSCANA RAPN Open VS. Simple Laparoscopic VS. Robot assisted procedures Dept. Of Urology, AOUC Careggi, Florence Jan Sept 2014 Open VLP Robot
40 Dati intraoperatori Clinica Urologica, AOUC Careggi Procedure Radical (non NS) (5,6%) NS Monolateral (18.3%) NS Bilateral (76.3%) Linfoadenectomy (8,9%) Operative time (min) mean (range) 208 (70 540) Consolle time (min) mean (range) 178 (40 510) Estimated Blood Loss (cc) mean (range) 240 (50 800)
41 Dati peri e postoperatori Clinica i Urologica, AOUC Careggi Open (1) Robot (2) P Catheter removal (day) 14 (10 21) 7 (6 12) Drainage removal (day) (3 34) 34) 3 (2 14) Length of hospitalization (days) 6.5 (4 36) 4 (2 16) 0.04 Positive surgical Open (1) Robot (2) P margins Overall 9.5% 16.1% < Apex Lateral Posterior pt2a b pt2c pt3a pt3b 4% 3.3% 2.1% 0 5.9% 11.2% 23.4% 5.1% 6.4% 4.6% 2.1% 13.2% 34.6% 35.7%
42 * Ratio drainage creatinine/serum creatinine 2 Complicanze Clinica i Urologica, AOUC Careggi Perioperative complications P OPEN (1) ROBOT (2) (INTRA + POST) Conversion to open 0 Bleeding requiring transfusion 3,4% 0,8% 0.08 Bleeding requiring reintervention 0,6% 0 Infections 5,2% 4,0% 0.55 Drain leakage for urine fistula * 4,6% 2,7% Reintervention for urine fistula 0 0 Drain leakage for lymphorrea 7,6% Not applicable Thrombosis/Embolisms 2,1% 1,3% 0,74 Bowel lesions (suture) 1,2% 0,4% 0.65 Overall surgical complications 24% 9,1% 0,0001 Clavien grade 3 4 surgical complications 4,9% 0,4% 0,0007 Cardiac/respiratory 3,4% 3,5% 0,89
43 Continenza Clinica i Urologica, AOUC Careggi URINARY CONTINENCE Open (1) Robot (2) P (zero pad) 1 month 46.8% 64.4 % month 79.5 % 82.7 % month 87.2 % 88.0 % month 92.3 % 94.1 % 0.559
44 Potenza Clinica i Urologica, AOUC Careggi NS Bilateral 6 months potency rate: Open (1) RALP (2) P 38.3% 77.7% 74.3% 79.5% 0.24 NS Monolateral 29% 17.3% 6 months potency rate: 43.0% 62.5% Non NS 32.7% 8.4% 6 months potency rate:
45 UTILIZZO DEL SISTEMA ROBOTICO «MONODISCIPLINARE» ANOMALIA??
46
Questions to Ask My Doctor About Prostate Cancer
Questions to Ask My Doctor Being told you have prostate cancer can be scary and stressful. You probably have a lot of questions and concerns. Learning about the disease, how it s treated, and how this
More informationQuestions to ask my doctor: About prostate cancer
Questions to ask my doctor: About prostate cancer Being diagnosed with prostate cancer can be scary and stressful. You probably have a lot of questions and concerns. Learning about the disease, how it
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationThe Business of Prostate Cancer Care: A Clinician-Researcher s Perspective
The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective David F. Penson, MD, MPH Departments of Urology and Preventive Medicine Keck School of Medicine University of Southern California
More informationRobotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology
Robotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology Prostate Cancer Epidemiology: 2009 Estimated new cases: 230,000 Estimated deaths:
More informationThomas A. Kollmorgen, M.D. Oregon Urology Institute
Thomas A. Kollmorgen, M.D. Oregon Urology Institute None 240,000 new diagnosis per year, and an estimated 28,100 deaths (2012) 2 nd leading cause of death from cancer in U.S.A. Approximately 1 in 6 men
More informationSIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon
SIOG Guidelines Update 2014 Prostate Cancer Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou
More informationFacing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery
Facing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery The Condition: Prostate Cancer Your prostate is a walnut-sized gland that is part of the male reproductive system. The prostate
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More informationPROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology
PROSTATE CANCER Get the facts, know your options Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology i What is the Prostate? Unfortunately, you have prostate
More informationProstate Cancer Treatment Comparison
Prostate Cancer Treatment Comparison Treatment Comparative Data Outcome Comparison: Surgery vs. Radiotherapy Outcome Radical Prostatectomy* Radiation** Survival duration compared to conservative disease
More informationProstate Cancer. Treatments as unique as you are
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
More informationProstate Cancer Treatment Comparison
Prostate Cancer Treatment Comparison Treatment Comparative Data Outcome Comparison: Surgery vs. Radiotherapy Outcome Radical Prostatectomy* Radiation** Survival duration compared to conservative disease
More informationCancer research in the Midland Region the prostate and bowel cancer projects
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
More informationGleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated
patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the
More informationPrecise, Minimally Invasive Prostate Cancer Removal
Precise, Minimally Invasive Prostate Cancer Removal Learn why da Vinci Surgery may be your best treatment option 1 Beyond Minimally Invasive For Prostate Cancer 1 Facing Prostate Cancer Prostate cancer
More informationTherapies for Prostate Cancer and Treatment Selection
Prostatic Diseases Therapies for Prostate Cancer and Treatment Selection JMAJ 47(12): 555 560, 2004 Yoichi ARAI Professor and Chairman, Department of Urology, Tohoku University Graduate School of Medicine
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationda Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy)
da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy) Prostate Cancer Overview Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the
More informationReal Time MRI guided Focal Laser Ablation Therapy for Prostate Cancer
Real Time MRI guided Focal Laser Ablation Therapy for Prostate Cancer A/Prof Celi Varol and Dr Orit Raz Uro-Oncologist Nepean and Macquarie Hospital Trial at Macquarie University Hospital Ethics board
More informationSRO Tutorial: Prostate Cancer Treatment Options
SRO Tutorial: Prostate Cancer Treatment Options May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible,
More informationProstate Cancer What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer?
Prostate Cancer What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer? Stacy Loeb, Edward M. Schaeffer, Bruce J. Trock, Jonathan I. Epstein, Elizabeth B. Humphreys, and Patrick C.
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More information4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective
Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light
More informationCYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA
CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results Alan Katz MD JD Flushing, NY USA Prostate Ablative Therapy Over the last 10 years our therapy has improved bned rates for LDR/HDR
More informationPATIENT GUIDE. Localized Prostate Cancer
PATIENT GUIDE Localized Prostate Cancer The prostate* is part of the male reproductive system. It is about the same size as a walnut and weighs about an ounce. As pictured in Figure 1, the prostate is
More informationThe 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6
More informationTreatment of Incidental Prostate Cancer Diagnosed during BPH Surgery with Radical Prostatectomy: Appropriate or over Treatment?
Journal of Cancer Therapy, 2012, 3, 256-262 http://dx.doi.org/10.4236/jct.2012.34036 Published Online August 2012 (http://www.scirp.org/journal/jct) Treatment of Incidental Prostate Cancer Diagnosed during
More informationYour Health Matters. Localized Prostate Cancer and Its Treatment
Your Health Matters Localized Prostate Cancer and Its Treatment Greetings! Understanding prostate cancer and choosing among the various treatment options can be a difficult and anxiety-arousing process.
More informationSecondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More informationCMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014
Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is
More informationDoes my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier
More informationProstate cancer is the second most
Treatment Options for Localized Prostate Cancer RAVINDER MOHAN, MD, PhD, and PAUL F. SCHELLHAMMER, MD Eastern Virginia Medical School, Norfolk, Virginia In the United States, more than 90 percent of prostate
More informationRoswell Park scientists and clinicians:
The Prostate Cancer Center at Roswell Park Connects You to Nationally Recognized Experts for State-of-the-Art Treatment Options and Compassionate, Evidence-based Care Founded in 1898, Roswell Park Cancer
More information855-DRSAMADI or 212-241-8779
SMART SURGERY NEWS MARCH 2013 Dr. David Samadi 855-DRSAMADI or 212-241-8779 YOUR PROSTATE CANCER NEWS PREVENTION DIAGNOSIS TREATMENT LIFE AFTER PROSTATE CANCER PREVENTION Prostate Cancer Need-to-Knows
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationA New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY
A New Biomarker in Prostate Cancer Care: Oncotype Dx David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY Learning Objectives Review the current challenges in the prediction and prognosis of
More informationACCEPTED MANUSCRIPT. Understanding the performance of active surveillance selection criteria in diverse urology practices
Understanding the performance of active surveillance selection criteria in diverse urology practices Scott R. Hawken BS*,1, Paul R. Womble MD*,1, Lindsey A. Herrel MD 1, Zaojun Ye MS 1, Susan M. Linsell
More informationClinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto
Clinical Trials and Radiation Treatment Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto What I will cover.. A little about radiation treatment The clinical trials
More informationProstate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.
Prostate cancer Christopher Eden The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Screening Screening men for PCa (prostate cancer) using PSA (Prostate Specific Antigen blood
More informationFAQ About Prostate Cancer Treatment and SpaceOAR System
FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop
More informationTreating Prostate Cancer
Treating Prostate Cancer A Guide for Men With Localized Prostate Cancer Most men have time to learn about all the options for treating their prostate cancer. You have time to talk with your family and
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationDefining Sexual Outcomes after Treatment for Localized Prostate Carcinoma
1773 Defining Sexual Outcomes after Treatment for Localized Prostate Carcinoma Leslie R. Schover, Ph.D. 1 Rachel T. Fouladi, Ph.D. 1 Carla L. Warneke, M.S. 1 Leah Neese, M.A. 1 Eric A. Klein, M.D. 2 Craig
More informationA Woman s Guide to Prostate Cancer Treatment
A Woman s Guide to Prostate Cancer Treatment Supporting the man in your life Providing prostate cancer support and resources for women and families WOMEN AGAINST PROSTATE CANCER A Woman s Guide to Prostate
More informationProton Therapy for Prostate Cancer: Your Questions, Our Answers.
Proton Therapy for Prostate Cancer: Your Questions, Our Answers. When you re looking for the right treatment for your prostate cancer, nothing s more important than accurate information. Read on, and learn
More informationPROSTATE CANCER. Diagnosis and Treatment
Diagnosis and Treatment Table of Contents Introduction... 1 Patient and Coach Information... 1 About Your Prostate... 1 What You Should Know About Prostate Cancer... 2 Screening and Diagnosis... 2 Digital
More informationDIAGNOSIS OF PROSTATE CANCER
DIAGNOSIS OF PROSTATE CANCER Determining the presence of prostate cancer generally involves a series of tests and exams. Before starting the testing process, the physician will ask questions about the
More informationRadiation Therapy for Prostate Cancer: Treatment options and future directions
Radiation Therapy for Prostate Cancer: Treatment options and future directions David Weksberg, M.D., Ph.D. PinnacleHealth Cancer Institute September 12, 2015 Radiation Therapy for Prostate Cancer: Treatment
More informationProstate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.
A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate
More informationthe risk of developing skeletal metastases or local recurrence.
Original Article SERUM PSA AND CLINICAL RECURRENCE AFTER RRP FOR LOCALIZED PROSTATE CANCER HAUKAAS et al. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence
More informationProstate Cancer Action Plan: Choosing the treatment that s right for you
Prostate Cancer Action Plan: Choosing the treatment that s right for you Segment 1: Introduction Trust me, there's a better way to choose a treatment for your prostate cancer. Watching this program is
More informationBasics on Treatment for prostate cancer
Basics on Treatment for prostate cancer SECTION 1: TREATMENTS This pamphlet provides information about different treatments for prostate cancer including what to expect and any risks and side-effects.
More informationFor further information on screening and early detection of prostate cancer, see the Section entitled Screening for Prostate Cancer.
Prostate Cancer For many older men, prostate cancer may be present but never cause symptoms or problems and many men will die with their prostate cancer rather than of their prostate cancer. Yet it remains
More informationBeyond the PSA: Genomic Testing in Localized Prostate Cancer
Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission
More informationOncological and functional outcomes of laparoscopic radical prostatectomy following fellowship training.
Oncological and functional outcomes of laparoscopic radical prostatectomy following fellowship training. Journal: BJU International Manuscript ID: Draft Manuscript Type: Original Article Date Submitted
More informationProstate cancer volume at biopsy vs. findings at Prostatectomy
Prostate cancer volume at biopsy vs. findings at Prostatectomy May 2005 By Shelly Smits, RHIT, CCS, CTR Ian Thompson, MD Data Source: Cancer registry data of prostate cancer treated with prostatectomy
More informationAdvances in Diagnostic and Molecular Testing in Prostate Cancer
Advances in Diagnostic and Molecular Testing in Prostate Cancer Ashley E. Ross MD PhD Assistant Professor Urology, Oncology, Pathology Johns Hopkins School of Medicine September 24, 2015 1 Disclosures
More informationUpdate on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward
Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of
More informationUse Of Testosterone In Men With Prostate Cancer. Traditional view: T is dangerous for PCa
Use Of Testosterone In Men With Prostate Cancer Abraham Morgentaler, MD, FACS Director, Men s s Health Boston Associate Clinical Professor of Urology Harvard Medical School Boston, USA Traditional view:
More informationNewly Diagnosed Prostate Cancer: Understanding Your Risk
Newly Diagnosed Prostate Cancer: Understanding Your Risk When the urologist calls with the life-changing news that your prostate biopsy is positive for prostate cancer, an office appointment is made to
More informationProstate Cancer Patients Report on Benefits of Proton Therapy
Prostate Cancer Patients Report on Benefits of Proton Therapy Dobson DaVanzo & Associates, LLC Vienna, VA 703.260.1760 www.dobsondavanzo.com Prostate Cancer Patients Report on Benefits of Proton Therapy
More informationAn Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
More informationNew Technologies in Surgery
New Technologies in Surgery Jim C. Hu MD, MPH Center for Advanced Surgical and Interventional Technology (CASIT) Director of Robotic and Minimally Invasive Surgery Associate Professor Department of Urology
More informationEarly Prostate Cancer: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:
More informationUnderstanding the. Controversies of. testosterone replacement. therapy in hypogonadal men with prostate cancer. controversies surrounding
Controversies of testosterone replacement therapy in hypogonadal men with prostate cancer Samuel Deem, DO CULTURA CREATIVE (RF) / ALAMY Understanding the controversies surrounding testosterone replacement
More informationFocal therapy for prostate cancer: seriously or seriously? Disclosures
Focal therapy for prostate cancer: seriously or seriously? Mitchell Kamrava, MD Assistant Clinical Professor Department of Radiation Oncology University of California Los Angeles Disclosures Speaking honorarium
More informationRobotic Assisted Laparoscopic Salvage Prostatectomy for Radiation Resistant Prostate Cancer
Robotic Assisted Laparoscopic Salvage Prostatectomy for Radiation Resistant Prostate Cancer Jonathan A. Eandi,* Brian A. Link, Rebecca A. Nelson, David Y. Josephson, Clayton Lau, Mark H. Kawachi and Timothy
More informationCyberknife Information Guide. Prostate Cancer Treatment
Cyberknife Information Guide Prostate Cancer Treatment CYBERKNIFE INFORMATION GUIDE PROSTATE CANCER TREATMENT As a patient recently diagnosed with localized prostate cancer, it is important that you familiarize
More informationProstate Cancer 2014
Prostate Cancer 2014 Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Incidence rates, US Men Mortality Rates, US Men
More informationHigh Intensity Focused Ultrasound for Prostate Cancer
High Intensity Focused Ultrasound for Prostate Cancer Patient Information Exploring a Minimally Invasive Prostate Cancer Therapy The Choice for HIFU Worldwide A Patient s Guide to Prostate Cancer and Sonablate
More informationThe PSA Controversy: Defining It, Discussing It, and Coping With It
The PSA Controversy: Defining It, Discussing It, and Coping With It 11 TH ANNUAL SYMPOSIUM ON MEN S HEALTH June 12, 2013 The PSA Controversy Defining It, Discussing It and Coping With It As of May 2012,
More informationNeoadjuvant and Adjuvant Hormone Therapy: How and When?
european urology supplements 7 (2008) 747 751 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neoadjuvant and Adjuvant Hormone Therapy: How and When? Hein Van Poppel * Department
More informationNATURAL HISTORY OF CLINICALLY STAGED LOW- AND INTERMEDIATE-RISK PROSTATE CANCER TREATED WITH MONOTHERAPEUTIC PERMANENT INTERSTITIAL BRACHYTHERAPY
doi:1.116/j.ijrobp.9..1 Int. J. Radiation Oncology Biol. Phys., Vol. 76, No., pp. 349 354, 1 Copyright Ó 1 Elsevier Inc. Printed in the USA. All rights reserved 36-316/1/$ see front matter CLINICAL INVESTIGATION
More informationACTION PLAN. Choosing the treatment that s right for you. Endorsed by Kaiser Permanente Inter-regional Chiefs of Urology
Prostate Cancer ACTION PLAN Choosing the treatment that s right for you Video Series Guidebook View videos at kpactionplans.org Endorsed by Kaiser Permanente Inter-regional Chiefs of Urology 2015 Kaiser
More informationWelcome to the February Edition of the Robotic Oncology Newsletter! February 2012
NEWSLETTER FROM DR. DAVID SAMADI TEL: 1-855-DRSAMADI or 1-212-241-8779 FAX: 1-212-308-6107 www.roboticoncology.com www.smart-surgery.com Welcome to the February Edition of the Robotic Oncology Newsletter!
More informationLocal Coverage Determination (LCD): MolDX: Genomic Health Oncotype DX Prostate Cancer Assay (L36153)
Local Coverage Determination (LCD): MolDX: Genomic Health Oncotype DX Prostate Cancer Assay (L36153) Contractor Information Contractor Name Palmetto GBA LCD Information Document Information LCD ID L36153
More informationEUROPEAN UROLOGY 65 (2014) 610 619
EUROPEAN UROLOGY 65 (2014) 610 619 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Comparisons of the Perioperative, Functional, and Oncologic Outcomes After
More informationThe PLCO Trial Not a comparison of Screening vs no Screening
PSA Screening: Science, Politics and Uncertainty David F. Penson, MD, MPH Hamilton and Howd Chair of Urologic Oncology Professor and Chair, Department of Urologic Surgery Director, Center for Surgical
More informationDevelopment of prostate cancer research database with the clinical data warehouse technology for direct linkage with electronic medical record system
Original Article Prostate Int 2013;1(2):59-64 P R O S T A T E INTERNATIONAL Development of prostate cancer research database with the clinical data warehouse technology for direct linkage with electronic
More informationIndividual Prediction
Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department
More informationThe 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Early detection of aggressive prostate cancer Challenges Serum PSA has a high false positive rate Over 1 million prostate biopsies performed
More informationProstate Cancer Treatment
Scan for mobile link. Prostate Cancer Treatment Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam,
More informationPrognostic factors in locally advanced prostate cancer as determined by biochemistry, imaging studies and pathology
Prognostic factors in locally advanced prostate cancer as determined by biochemistry, imaging studies and pathology Authors Key words C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel Prognostic
More informationSaturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies
Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies John F. Ward, MD Assistant Professor University of Texas M. D. Anderson Cancer Center Ablation
More informationPrecise, Minimally Invasive Prostate Cancer Removal
Precise, Minimally Invasive Prostate Cancer Removal Why da Vinci Surgery may be your best treatment option 1 Beyond Minimally Invasive For Prostate Cancer 1 Facing Prostate Cancer Prostate cancer is the
More informationUse of Androgen Deprivation Therapy (ADT) in Localized Prostate Cancer
Use of Androgen Deprivation Therapy (ADT) in Localized Prostate Cancer Adam R. Kuykendal, MD; Laura H. Hendrix, MS; Ramzi G. Salloum, PhD; Paul A. Godley, MD, PhD; Ronald C. Chen, MD, MPH No conflicts
More informationPCa Commentary. Volume 73 January-February 2012 PSA AND TREATMENT DECISIONS:
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 73 January-February 2012 CONTENTS PSA SCREENING & BASIC SCIENCE PSA AND TREATMENT 1 DECISIONS
More informationInformation for Men Newly Diagnosed with Prostate Cancer
Information for Men Newly Diagnosed with Prostate Cancer Urologists at the Vancouver Prostate Centre Martin E. Gleave M.D., FRCSC, FACS Director of the Vancouver Prostate Centre S. Larry Goldenberg OBC,
More informationProstate Cancer. What is prostate cancer?
Scan for mobile link. Prostate Cancer Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam, prostate-specific
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More informationNERVE GRAFT TO RESTORE ERECTILE FUNCTION DURING RADICAL PROSTATECTOMY
CLINICAL POLICY NERVE GRAFT TO RESTORE ERECTILE FUNCTION DURING RADICAL PROSTATECTOMY Policy Number: SURGERY 043.13 T Effective Date: October 1, 015 Table of Contents BENEFIT CONSIDERATIONS. APPLICABLE
More informationSaturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date
MP 7.01.101 Saturation Biopsy for Diagnosis and Staging of Prostate Cancer Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date /12/2013 Return to Medical Policy
More informationProstate Cancer & Its Treatment
Your Health Matters Prostate Cancer & Its Treatment By the UCSF Medical Center Prostate Cancer Advocates Greetings! From our personal experience in dealing with our own prostate cancers, we UCSF Patient
More informationTO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER
TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER DILEMMA Thomas J Stormont MD January 2012 http://www.youtube.com/watch?v=8jd 7bAHVp0A&feature=related related INTRODUCTION A government health panel (the
More informationProstate cancer screening. It s YOUR decision!
Prostate cancer screening It s YOUR decision! For many years now, a test has been available to screen for. The test is called the prostate-specific antigen blood test (or PSA test). It is used in combination
More informationREGISTRY OF IRREVERSIBLE ELECTROPORATION FOR THE ABLATION OF PROSTATE CANCER WITH USE OF NANOKNIFE DEVICE
REGISTRY OF IRREVERSIBLE ELECTROPORATION FOR THE ABLATION OF PROSTATE CANCER WITH USE OF NANOKNIFE DEVICE A Multi-Center, International Registry to evaluate the treatment of Prostate Cancer in terms of
More informationDevelopment of Prostate Cancer research database with the CDW technology. for direct linkage with electronic medical record system
Development of Prostate Cancer research database with the CDW technology for direct linkage with electronic medical record system In Young Choi 1, Seungho Park 2, Bumjoon Park 2, Ji Youl Lee 3 1. Department
More informationProstate Cancer Treatment: What s Best for You?
Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More information